CRISPR epigenome editing successfully reactivates silenced genes in Prader-Willi Syndrome, highlighting potential for ...

The CRISPR-Cas9 system offers groundbreaking genome editing capabilities, yet off-target cleavage raises concerns about ...

When developing a drug, it’s important to understand its target and its mechanism of action. This is particularly crucial when repurposing an abandoned asset from another indication. CRISPR ...

( Nanowerk News) The CRISPR-Cas gene scissors offer a wide range of potential applications, from the treatment of genetic ...

CRISPR-Cas9 genome editing exploits the CRISPR-Cas system to modify a genome in a targeted manner. Guided by RNA, the Cas9 endonuclease breaks DNA at a target sequence. Imprecise repair of the ...

CRISPR's upcoming trial data and increasing demand for Casgevy drive Evercore's bullish outlook and a higher price target ...

It's a real-life tractor beam that allows us to capture and manipulate objects in space.-David Rueda, Imperial College London CRISPR relies on two primary components: a guide RNA (gRNA) of 17-24 ...

Stifel analyst Benjamin Burnett lowered the firm’s price target on Crispr Therapeutics (CRSP) to $49 from $53 and keeps a Hold rating on the shares. The firm’s neutral thesis on the stock is ...

TD Cowen raised shares of CRISPR Therapeutics from a “sell” rating to a “hold” rating and set a $35.00 price target for the company in a research report on Wednesday.

The first generation of gene editing technology makes double-stranded breaks in DNA, which raises the risk of dangerous off-target edits. Some next-generation CRISPR systems that are in ...

BofA analyst Alec Stranahan raised the firm’s price target on Crispr Therapeutics (CRSP) to $86 from $85 and keeps a Buy rating on the shares. With sufficient cash to support “years of ...